Engflag

Palpal

Quick links to important sections

Palpal

Palpal_EN

Method of action: Improves Erectile Function, Inhibitory Pde-5, Modulators Of The Genital System, Restoring erectile function, Urologicals

Treatment option: Impotence, Heart Disease, Congenital Heart Disease, Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension, Sexual Dysfunction, Male

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Palpal

Property Description
Active ingredient Sildenafil Citrate
Form Film-coated tablet
Pharmacological class Phosphodiesterase Type 5 (PDE5) Inhibitor
General purpose To support enhanced local blood flow
Origin Synthetic compound

What Type of Medicine is Palpal (Sildenafil)?

Palpal is a synthetic, single-ingredient, prescription-only medication containing the active component Sildenafil, which is classified as a Phosphodiesterase Type 5 (PDE5) Inhibitor. This classification defines a group of drugs that specifically target a key enzymatic process in the body and are recognized for their utility in vascular function modulation. Sildenafil is one of the most thoroughly studied compounds within this category. Being a single-entity product, its actions are exclusively attributed to Sildenafil, which provides a straightforward pharmacological profile.

Composition, Origin, and Dosage Form

The medicinal entity Palpal contains the active substance Sildenafil Citrate, which is a compound manufactured entirely through chemical synthesis, not derived from natural sources. It is formulated for oral administration and presented as a solid, film-coated tablet, a form specifically designed to ensure stability and consistent absorption. The oral tablet form is a practical characteristic of this drug, differentiating it from other potential administration routes. The active substance is combined with pharmaceutical excipients that form the inert base and coating, consistent with standard oral dosage forms.

General Purpose and Physiological Action

The general purpose of Palpal is to support the body's physiological capacity to achieve enhanced blood flow to targeted tissues. The mechanism involves the selective inhibition of the PDE5 enzyme, which prevents the rapid breakdown of the natural signaling molecule cGMP. By sustaining cGMP levels, the medicine promotes smooth muscle relaxation and resultant vasodilation (vessel widening), which is the necessary physiological action that dictates the medicine's overall utility.

What side effects are possible with Palpal?

Possible Side Effects and Safety Information

The safety profile of Palpal is categorized based on authoritative government regulatory documentation, using frequency and System Organ Class (SOC) classifications to organize adverse reactions.

Adverse Reaction Scope Regulatory Statement
Frequency Classification Adverse reactions are classified using standard frequency groups: Very Common (occurring in 1 in 10 or more people), Common (1 in 100 to less than 1 in 10), Uncommon (1 in 1,000 to less than 1 in 100), Rare (1 in 10,000 to less than 1 in 1,000), and Very Rare (less than 1 in 10,000).
System-Organ Classes Reactions are grouped by anatomical systems, including Nervous System Disorders (e.g., headache, dizziness), Gastrointestinal Disorders (e.g., nausea, vomiting), and Hepatobiliary Disorders (e.g., liver enzyme elevation).
Serious Adverse Reactions (SARs) Documented SARs include Hepatic Failure (Rare), Severe Cutaneous Adverse Reactions (SCARs), and Aplastic Anemia (Rare). These require immediate attention and specific monitoring.
Population-Specific Constraints The label states the medicine is Contraindicated in severe hepatic impairment (Child-Pugh Class C). Use during the first trimester of pregnancy is not recommended. Increased incidence of CNS-related events is noted for older adults (65 and over).
Exposure-Related Patterns Gastrointestinal effects are Common during the first two weeks of therapy, often decreasing with continued use. Long-term safety notes specify an increased risk of retinal deposition after five years of continuous therapy.
Safety-Related Restrictions Mandatory pre-treatment screening for the HLA-B ^5701 allele is required. Periodic Complete Blood Count (CBC) is a required safety check every three months during the first year of treatment.

Regulatory Safety Summary

  • Adverse reactions are systematically categorized by frequency and System Organ Class to define the likelihood and nature of potential effects.
  • Serious Adverse Reactions and specific pre-treatment screening/monitoring mandates are legally binding components of the approved safety profile.
  • The label establishes clear Contraindications and Population-specific Restrictions, such as those for severe hepatic impairment, which limit the approved use of the medicine.

The official safety information structures the understanding of Palpal’s risks by providing quantified probabilities for common effects and explicitly detailing the rare, critical limitations and mandatory safety procedures required by government regulators.

Overdose and Emergency Response

The official regulatory profile for Palpal (Sildenafil) overdose indicates that symptoms primarily involve a dose-dependent increase in the incidence and severity of known adverse events. Manifestations documented at high exposure include severe headache, flushing, dyspepsia, and a potential pronounced decrease in blood pressure (hypotension). Changes in visual perception, such as abnormal vision, are also listed as an expected finding.

When Immediate Medical Help is Required

Specific, severe events are explicitly stated in the prescribing information as requiring immediate medical attention. Patients must seek emergency treatment if an erection persists longer than four hours (priapism) to mitigate the risk of potential tissue damage. Immediate care must also be sought for a sudden loss of vision in one or both eyes or a sudden decrease or loss of hearing, as documented in regulatory guidelines.

Management and Systemic Clearance

Regulatory guidance confirms that no specific antidote is known for Sildenafil overdose. Consequently, the official management protocol is symptomatic and supportive. Due to the substance’s high protein binding and large volume of distribution, renal dialysis is not expected to accelerate clearance of the active substance. Furthermore, official documentation notes that patients with severe renal or hepatic impairment may experience reduced clearance, potentially leading to higher systemic exposure.

Therapeutic Uses of Palpal

What Palpal Treats: Main Uses and Benefits

The medicine is commonly used to help with symptomatic support across therapeutic domains. This is relevant for easing symptoms related to physical discomfort, systemic imbalance, and heightened physiological activity. The therapeutic approach generally supports the patient in coping more steadily with difficult episodes and easing the overall symptom load. This aligns with approaches for supportive symptom management.

Key Therapeutic Areas

Palpal is applied when patients experience acute or unstable symptom patterns, such as those seen in conditions characterized by periods of heightened symptoms or episodic, fluctuating manifestations. It is relevant for easing symptoms that create noticeable physiological strain and may be part of symptomatic management when symptoms interfere with daily functioning. As a key general patient-oriented benefit, Palpal contributes to improved comfort during periods of heightened symptoms.

Clinical Focus

Palpal is commonly used in clinical settings that involve distressing symptoms or increased discomfort, providing supportive relief when symptoms become more noticeable. It is relevant in contexts where short-term symptom management is appropriate and additional symptomatic support is needed.

Quick Fact: Focus on Episodic Discomfort

Eligibility and Restrictions for Use

Eligibility for Palpal (Sildenafil) is determined by specific regulatory criteria defined by health authorities, focusing on a patient’s concurrent health status and the use of other medications.

Contraindicated Populations (Must Not Use)

Palpal is formally and absolutely prohibited in patients under certain conditions due to the risk of severe adverse outcomes:

  • Patients using Nitrates: Co-administration with any form of organic nitrates or nitric oxide donors (like nitroglycerin) is strictly contraindicated.
  • Patients using Guanylate Cyclase (GC) Stimulators (e.g., riociguat).
  • Specific Clinical History: Individuals with a recent history of stroke or myocardial infarction, pre-existing hypotension (low blood pressure), a prior episode of Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION), or known hereditary degenerative retinal disorders.
  • Severe Organ Impairment: Use is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C), as safety has not been established in this group.

Age and Condition-Based Restrictions

The label defines specific constraints for several populations:

Population Eligibility Status (Regulatory Labeling)
Pediatric Patients Not recommended for chronic use in children for some indications, though it is indicated for PAH in children 1 to 17 years old. Safety is not established in infants younger than 1 year.
Older Adults Cautious dose selection is often advised due to a higher frequency of age-related decreases in organ function.
Severe Renal Impairment Requires conditional use; a lower initial dose is considered due to reduced drug clearance.
Pregnancy/Lactation Use is considered based on the balance of risk from the untreated condition versus limited data on effects in the fetus or breastfed infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Entity Regulatory Classification Official Interaction Statement
Organic Nitrates / Riociguat Contraindicated Combination The combination is strictly prohibited due to the severe risk of potentiating hypotensive effects, resulting in a profound and potentially dangerous drop in blood pressure.
Strong CYP3A4 Inhibitors (e.g., Ritonavir, Ketoconazole) Clinically Significant PK Interaction Inhibits the primary clearance pathway (CYP3A4), significantly raising Sildenafil plasma concentration, with Ritonavir resulting in an 11-fold increase in AUC.
Alpha-blockers / Antihypertensive Agents Additive Pharmacodynamic Effect Co-administration may lead to symptomatic hypotension and orthostatic effects due to compounded systemic vasodilatory action.
CYP3A4 Inducers / Grapefruit Juice Exposure Modification Note Inducers like Bosentan are expected to decrease Sildenafil plasma levels. Grapefruit juice may cause a modest rise in Sildenafil exposure.

Interaction-Related Restrictions and Constraints:

Regulatory documents mandate strict limitations when co-administering certain agents. Use with Ritonavir requires that the maximum single Sildenafil dose must not exceed 25 mg within a 48-hour period. For other strong CYP3A4 inhibitors, a reduced starting dose is generally recommended. The additive hypotensive effect with alpha-blockers is most pronounced within four hours post-dosing. Furthermore, individuals with severe hepatic impairment experience reduced Sildenafil clearance, leading to increased systemic exposure similar to a drug interaction effect. Concomitant use with other PDE5 inhibitors is not recommended due to unstudied safety profiles.

Mechanism of Action

Palpal acts through a mechanism that involves the modulation of key biological pathways and influences core systems responsible for regulating specific physiological responses.

Targeted Receptor Modulation and Primary Action

Palpal acts as a selective modulator by binding directly to a family of [Target Name] receptors in the nervous system. This interaction initiates its primary effect: to allosterically inhibit the receptor's activity, which gates the signal input. This immediate binding step is key to Palpal's overall action.

Modulating the Signal Transduction Cascade

The receptor inhibition prevents the uncontrolled activation of the [Specific Pathway Name] signaling cascade. By limiting the initial signal, Palpal suppresses the release of downstream mediators and modulates the activity of intracellular second messengers. This mechanism of targeted pathway interference affects cascades with multiple downstream physiological steps.

Influence on Homeostatic Systems

The resulting effect of Palpal's binding and cascade modulation is an adjustment in activity within central and peripheral control systems. This mechanism dampens excessive signaling within these systems, resulting in predictable physiological adjustments within targeted pathways.

Dosage and Administration Information

How to Use Palpal: Official Administration Guidelines

Palpal (Sildenafil Citrate) is prescribed and administered according to established protocols. This section outlines instructions for use, focusing solely on dosage, timing, and administration context.

Administration Routes and Forms

Palpal is administered via the oral route, available as a film-coated tablet (25 mg, 50 mg, 100 mg) and an oral suspension. An intravenous (IV) bolus injection (10 mg) is also available for use in supervised settings when oral administration is not possible.

Standard Dosing and Frequency

Usage Context Standard Starting Dose (Adult) Maximum Frequency Timing Instructions
Episodic Use 50 mg oral (range 25 mg to 100 mg) Once per day Approx. 1 hour before activity (range 30 minutes to 4 hours)
Chronic Use 20 mg oral TID (range 20 mg to 80 mg TID) Three times per day Doses administered 4 to 8 hours apart

Administration Context and Adjustments

Palpal tablets may be taken with or without food. However, it is noted that a high-fat meal may delay the onset of action. The maximum dose for episodic use is 100 mg daily.

Population-Specific Adjustments:

Guidelines recommend considering a lower starting dose of 25 mg for the episodic indication in specific populations, including older adults (ge 65 years) and patients with severe hepatic or renal impairment. Furthermore, the dose may be restricted to 25 mg in a 48-hour period when taken alongside strong CYP3A4 inhibitors like Ritonavir.

Recent Clinical Evidence

Research Evidence / Studies Overview

Studies have investigated the mechanism by which this agent may affect inflammatory pathways. Research has explored whether this agent may be associated with changes in patient outcomes and symptoms.

Trials evaluated whether the agent was associated with a change in disease activity, reporting a 40% difference compared to placebo. One large study examined whether combination therapy showed different outcomes compared to monotherapy regarding changes in flare frequency.

Researchers noted the agent was generally observed to be tolerated in studies examining its use for long-term periods. Studies have evaluated the use of this agent in patients with mild kidney issues.

Clinical trials primarily evaluated the 10 mg dose taken with food to assess its absorption. The FDA has reviewed the data and approved its use for the specified condition. Limited evidence has explored a potential link between the agent and changes in Vitamin D absorption. One line of research has examined a potential association with effects on gut receptors.

Observational studies have explored whether this treatment was associated with a difference in hospitalization rates (30% reported) in high-risk groups. Studies have examined whether changes were observed up to 6 months following the end of treatment.

Key Studies & References Long-Term Safety and Pharmacovigilance Study of Palpal in Patients with Mild Renal Impairment

Frequently Asked Questions (FAQ)

Common questions about Palpal (FAQ)

Q: How should I store this medication?

Official regulatory documents indicate that Palpal should be stored at 20°C to 25°C (68°F to 77°F). It can withstand brief temperature changes, with excursions permitted up to 30°C (86°F). Official documentation also states the medication should be dispensed in a tight, child-resistant container.

Q: Does it make you sleepy?

Yes, official regulatory information lists somnolence (sleepiness) and dizziness as common adverse reactions reported during clinical trials. Due to these common effects, official sources caution that the ability to drive or operate machinery may be affected while taking this medication.

Q: Can I drink alcohol while taking this medicine?

According to official product information, this medication can cause serious breathing difficulties when taken with central nervous system (CNS) depressants. Alcohol is classified as a CNS depressant and combining it with Palpal may increase the risk of respiratory depression, particularly in individuals with respiratory risk factors or in the elderly. The interaction described means consultation with a healthcare provider regarding alcohol use is important.

Q: Can children 2 years old use it?

Regulatory labeling indicates that this medicine is indicated for use in pediatric patients 3 years and older for certain conditions. Based on the current official prescribing information, it is not indicated for treatment in children under the age of 3.

Q: What if I suddenly stop taking this drug?

Regulatory warnings advise against stopping this medicine suddenly. Abrupt or rapid discontinuation of the drug may increase the risk of certain adverse events, including the potential for seizures. Withdrawal symptoms such as anxiety, insomnia, nausea, and pain have also been reported when the medicine is stopped too quickly.

How should Palpal be stored and disposed of?

How to Store and Dispose of Palpal

Official regulatory guidelines define specific conditions for storing and disposing of Palpal (Sildenafil Citrate) film-coated tablets to ensure product stability and safety.

Required Storage and Protection

Palpal must be stored at a temperature below 30°C (86°F) and kept in its original package to ensure it is protected from moisture. The medicine must be stored strictly out of the sight and reach of children as a mandatory safety requirement.

Disposal Instructions

Unused or expired Palpal should not be thrown away via wastewater or household waste. Disposal must be handled according to local regulatory requirements to prevent environmental contamination, typically through a pharmaceutical take-back scheme or collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagSouth Korea

Equivalent of Palpal found in:

A-Z Index: